Prevention of Alzheimer disease (AD) dementia can be accomplished by retarding the progression of the disease in its presymptomatic stages, thus postponing the onset of clinical symptoms. Hence, research on the identification and development of AD preventives can be aided by quantitative measures of disease progression before symptom onset.^[@R1]^ Such presymptomatic disease progress may be revealed by subtle cognitive changes, various MRI or PET imaging techniques, or AD biomarkers in the CSF. These measures are generally inconvenient, and more accessible markers of preclinical AD pathology are needed.

Because rhinencephalic brain regions are especially vulnerable to AD pathology,^[@R2]^ a candidate marker for this purpose may be odor identification (OI), i.e., the ability to identify and name specific odorants.^[@R3][@R4][@R10]^ Like cognition, OI is known to be impaired in both aging^[@R11],[@R12]^ and dementia.^[@R7],[@R13],[@R14]^ In longitudinal studies, reduced OI performance predicts faster cognitive decline in elderly controls and persons with mild cognitive impairment or AD dementia.^[@R5],[@R8][@R9][@R10],[@R15][@R16][@R17]^ Finally, an important study of cognitively healthy persons showed that reduced OI ability predicted postmortem AD pathology.^[@R5]^

We therefore sought to evaluate OI as a measure of presymptomatic AD pathogenesis. In a study of aging asymptomatic individuals at risk of AD dementia, we investigated the association between OI and recognized in vivo AD biomarkers such as CSF total tau (t-tau) and phospho-tau (P~181~-tau) and their ratio with Alzheimer β-amyloid (Aβ~1-42~). We hypothesized that degree of impairment in OI would predict biomarker evidence of AD neuropathology.

METHODS {#s1}
=======

The PREVENT-AD cohort. {#s1-1}
----------------------

We investigated cross-sectional baseline measures from 274 participants in a cohort of cognitively unimpaired individuals assembled for Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer\'s Disease (PREVENT-AD).^[@R1]^ PREVENT-AD enrollees had a parent or multiple siblings with a history of AD-like dementia. They were ≥60 years of age, except that individuals 55 to 59 years old were eligible if their current age was within 15 years of dementia onset in their youngest-affected relative. In general, persons with a first-degree family history have an elevated risk of AD.^[@R18]^ We first screened their cognitive state using the Montreal Cognitive Assessment^[@R19]^ and the Clinical Dementia Rating scale.^[@R20]^ Individuals with questionable cognitive difficulties underwent a formal neuropsychological assessment. We analyzed data collected between September 2011 and August 2015 and archived in PREVENT-AD data release 2.0.

Nested within PREVENT-AD was a randomized trial of Impact of Naproxen Treatment on Presymptomatic Alzheimer\'s Disease (INTREPAD), a placebo-controlled, biomarker-endpoint prevention trial of the nonsteroidal anti-inflammatory drug naproxen in 184 participants. We obtained CSF data from a subset of 101 volunteers from that trial.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

Written informed consent was obtained at each stage of the research from all participants and their collateral partners. Protocols and French and English consent forms were approved by the Institutional Review Board of the McGill University Faculty of Medicine. INTREPAD is registered with [clinicatrials.gov](http://clinicatrials.gov) as NCT02702817. The research was conducted in compliance with the ethics principles of the Declaration of Helsinki. For additional information, see [www.prevent-alzheimer.ca](http://www.prevent-alzheimer.ca/).

Methods of assessment. {#s1-3}
----------------------

### Review of health and neurocognitive status. {#s1-3-1}

Participants were evaluated while accompanied by an informant. Assessments included a health history and review of systems, a standardized neurologic examination, and a cognitive examination with version A of the Repeatable Battery for Assessment of Neuropsychological Status (RBANS).^[@R21]^ The RBANS is available in both English and Canadian French. It measures 5 domains of cognitive performance. Participants also underwent phlebotomy for routine laboratory tests and banking of plasma and a multimodal MRI/fMRI scan session.

### CSF collection. {#s1-3-2}

INTREPAD volunteers\' lumbar punctures were performed in the morning after an overnight fast. CSF was collected with the Sprotte 24-gauge atraumatic needle. The time of collection was recorded. All procedures followed recommendations of the BiomarkAPD project in the EU Joint Programme in Neurodegeneration.^[@R22]^ Briefly, CSF was centrifuged at 3,000 RPM (2,000*g*) at room temperature to precipitate cells and other insoluble material. Within 4 hours of collection, CSF samples were frozen and stored in 0.4-mL aliquots at −80°C in 500 μL polypropylene cryotubes. The samples went through only one freeze-thaw cycle. We assayed CSF t-tau, P~181~-tau, and Aβ~1-42~ levels using the Innotest/Fujirebio (previously Innogenetics, Ghent, Belgium) ELISA kit, again following Joint Programme in Neurodegeneration--specified procedures. This technology is based on specific fluorescent antibody labeling. We used the biomarker ratios CSF t-tau/Aβ~1-42~ and P~181~-tau/Aβ~1-42~ to indicate disease state.

### APOE genotyping. {#s1-3-3}

DNA was extracted automatically from buffy coat samples with the QiaSymphony DNA mini kit (Qiagen, Toronto, ON, Canada). *APOE* genotype was determined with the PyroMark Q96 pyrosequencer (Qiagen). The DNA was amplified using reverse transcriptase--PCR, forward primers 5′-ACGGCTGTCCAAGGAGCTG-3′ (rs429358) and 5′-CTCCGCGATGCCGATGAC-3′ (rs7412), and reverse biotinylated primers 5′-CACCTCGCCGCGGTACTG-3′ (rs429358) and 5′-CCCCGGCCTGGTACACTG-3′ (rs7412). The DNA was sequenced with these primers: 5′-CGGACATGGAGGACG-3′ (rs429358) and 5′-CGATGACCTGCAGAAG-3′ (rs7412).

### Odor identification. {#s1-3-4}

We assessed OI abilities using the 40-item University of Pennsylvania Smell Identification Test (UPSIT).^[@R23]^ This test includes a simple scratch-and-sniff booklet along with multiple-choice response forms for OI. The UPSIT has been validated in people 5 to 85 years of age and shows a test-retest reliability of *r* = 0.92 to 0.95.^[@R24],[@R25]^ Its score is computed as the sum of the correct responses of a maximum possible 40. Both francophone and anglophone participants were presented with odors from the US version of the UPSIT. The francophone test used an in-house French translation. In a leave-one-out analysis, we assessed the reliability of the UPSIT in the PREVENT-AD cohort among an initial sample of 159 participants, obtaining a Cronbach α of 0.821, which suggests high internal consistency.

Data analyses. {#s1-4}
--------------

To avoid left skewness and a leptokurtic distribution, we transformed the raw OI scores to an UPSIT error score of log~10~ (41 − raw UPSIT score), as described by Moberg et al.^[@R26]^ Higher transformed scores thus represented greater deficit in OI. We used a Kruskal-Wallis test to compare scores in *APOE* ε4 carriers and noncarriers. To assess the main effects on OI of various indicators of interest, we first examined bivariate relationships using simple linear regression. To examine the effect of each predictor variable in full perspective, we then constructed multivariable models, iteratively adding measures individually or in combination. Both the bivariate and multivariable analyses used robust-fit linear regression with a tuning constant of 1.205 to down-weight outliers. The latter general linear model analyses considered, in various combinations, age, sex, years of education, *APOE* ε4 carrier status, RBANS total score (global cognition), and the CSF t-tau/Aβ~1-42~ ratio (sometimes substituted as specified below by other CSF indicators of AD pathogenesis). Adjusting for age, sex, years of education, and *APOE* ε4 carrier status enabled us to compare our work to other highly cited findings.^[@R5],[@R6]^ We verified the absence of collinearity in the multivariable models by investigating the variance inflation factor and tolerance. To test our primary hypothesis, we explored the relationships between OI and CSF AD biomarkers, seeking identifiable subgroups and examining interaction terms of interest.

Two sensitivity analyses assessed the effects of potential confounders on olfactory function. For both analyses, we grouped available data on brain injury, TIA, and stroke into a binary categorical variable called brain health. A second binary variable grouped nasal polyps, nasal surgeries, deviated septum, and history of a broken nose. A third such variable identified participants with a history of asthma, and a fourth identified current smokers of any substance. A final potential confounder characterized participants with any of the foregoing conditions (past or present) mentioned only at the time of olfactory testing. The first sensitivity analysis added all 5 of these potential confounders as covariates in the analytic framework of model 7. The other was a version of model 7 that excluded data from all participants with a positive rating on any of the 5 potential confounding variables.

RESULTS {#s2}
=======

Of the 274 PREVENT-AD participants who met inclusion and exclusion criteria, 1 individual who consented for a lumbar puncture did not consent to the OI test. RBANS test results were lost for 4 participants. We excluded data from 8 participants who had incomplete test scores or nasal congestion on the day of testing. The analytic sample then comprised 265 PREVENT-AD participants, including 100 INTREPAD lumbar puncture volunteers who had complete CSF biomarker and OI data. The participant pool included predominantly francophone and female individuals who were well educated. As expected, their proportion of *APOE* ε4 carriers was higher than population norms ([table 1](#T1){ref-type="table"}). The INTREPAD participants from whom we collected CSF were slightly younger than other INTREPAD participants and had a higher proportion of francophone individuals and slightly lower Montreal Cognitive Assessment scores. The CSF donors appeared demographically similar to the entire PREVENT-AD group of 274 PREVENT-AD enrollees ([table 1](#T1){ref-type="table"} and table e-1 at [Neurology.org](http://neurology.org/lookup/doi/10.1212/WNL.0000000000004159)).

###### 

Demographics of INTREPAD participants
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In bivariate modeling, the UPSIT error score was higher in older participants (n = 265, β = 0.0134, *p* = 2.24 ×10^−6^; figure e-1) and in participants with lower RBANS total score (n = 261, β = −0.00666, *p* = 1.28 ×10^−6^; figure e-1). However, because we were interested especially in the CSF AD biomarker data, we also evaluated models restricted to the 100 participants who had both OI and CSF data. In the reduced sample, the statistical association with older age was seen only at a trend level (β = 6.79 ×10^−3^, *p* = 0.095; figure e-2), but the association of reduced OI with decreased cognition remained robust (β = −4.76 ×10^−3^, *p* = 0.011; figure e-2). Similar unadjusted analyses showed strong association between higher UPSIT error score and increased values of CSF t-tau/Aβ~1-42~ (β = 0.286, *p* = 4.94 ×10^−3^), P~181~-tau/Aβ~1-42~ (β = 1.77, *p* = 0.0165), and CSF t-tau levels (β = 3.61 ×10^−4^, *p* = 0.0257; [figure 1](#F1){ref-type="fig"}). There was a weaker but still suggestive relationship between increased UPSIT error score and elevated CSF P~181~-tau (β = 2.10 ×10^−3^, *p* = 0.0724) but no relationship with Aβ~1-42~ alone (β = −7.01 × 10^−5^, *p* = 0.359).

![Robust-fit linear regression models of UPSIT error score vs CSF biomarkers of AD\
(A) CSF t-tau/Aβ~1-42~ (β = 0.287, *p* = 0.00494, n = 100). (B) CSF P~181~-tau/Aβ~1-42~ (β = 1.77, *p* = 0.0165, n = 100). (C) CSF t-tau (β = 3.61 ×10^−4^, *p* = 0.0257, n = 100). (D) CSF P~181~-tau (β = 2.10 ×10^−3^, *p* = 0.0724, n = 100). (E) CSF Aβ~1-42~ (β = −7.01 ×10^−5^, *p* = 0.359, n = 100) and in individuals with CSF Aβ~1-42~ levels below the 25th percentile (β = −0.000827, *p* = 0.0135, n = 25). (F) CSF t-tau/Aβ~1-42~ in individuals with CSF Aβ~1-42~ levels below the 25th percentile (β = 0.399, *p* = 0.00260, n = 25). In panel (E), blue circles represent the top 3 quartiles for Aβ concentrations, while red circles in panels (E) and (F) are data from the lowest quartile of Aβ concentrations (suggesting that they have more advanced preclinical AD). Aβ = β-amyloid; AD = Alzheimer disease; P~181~-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.](NEUROLOGY2017798520FF1){#F1}

We observed no group difference in OI between *APOE* ε4 carriers and noncarriers (n = 262, *p* = 0.271). A similar result was observed in the reduced sample of 100 participants with CSF (*p* = 0.7129). However, previously observed correlations between UPSIT error score and several CSF markers of AD pathology were now apparent only in ε4 carriers. In contrast to unstratified samples, the carriers showed an association between higher UPSIT error scores and reduced levels of Aβ~1-42~ (n = 33, β = −3.76 ×10^−4^, *p* = 0.00841). In keeping with previously noted findings, UPSIT error score was associated in the ε4 carriers with higher t-tau/Aβ~1-42~ (β = 0.352, *p* = 0.0158) and P~181~-tau/Aβ~1-42~ (β = 2.416, *p* = 0.0270), but a comparable association appeared only at a trend level for t-tau (β = 4.68 ×10^−4^, *p* = 0.0914) and not at all for P~181~-tau (β = 2.76 ×10^−3^, *p* = 0.204; [figure 2](#F2){ref-type="fig"}). In addition, we saw that individuals with lowest CSF Aβ~1-42~ levels appeared to have a higher proportion of *APOE* ε4 carriers (supplemental materials).

![Robust-fit linear regression models of UPSIT error score vs CSF biomarkers, stratified by *APOE* ε4 status\
Red circles represent *APOE* ε4 carriers. Blue circles represent *APOE* ε4 noncarriers. (A) CSF t-tau/Aβ~1-42~ in carriers (β = 0.352, *p* = 0.0158, n = 33) and in noncarriers (β = 0.252, *p* = 0.131, n = 67). (B) CSF P~181~-tau/Aβ~1-42~ in carriers (β = 2.416, *p* = 0.0270, n = 33) and in noncarriers (β = 0.980, *p* = 0.408, n = 67). (C) CSF t-tau in carriers (β = 4.68 ×10^−4^, *p* = 0.0914, n = 33) and in noncarriers (β = 0.000312, *p* = 0.144, n = 67). (D) CSF P~181~-tau in carriers (β = 2.76 ×10^−3^, *p* = 0.204, n = 33) and in noncarriers (β = 0.00178, *p* = 0.218, n = 67). (E) CSF Aβ~1-42~ in carriers (β = −3.76 ×10^−4^, *p* = 0.00841, n = 33) and in noncarriers (β = 4.890e−05, *p* = 0.598, n = 67). Aβ = β-amyloid; AD = Alzheimer disease; P~181~-tau = phospho-tau; t-tau = total tau; UPSIT = University of Pennsylvania Smell Identification Test.](NEUROLOGY2017798520FF2){#F2}

The multiple linear regression models assessed the relationships between OI and age, cognition, and CSF biomarkers added sequentially in models adjusted for sex, education, and *APOE* ε4 carrier status. Multivariable models from the full PREVENT-AD dataset (without CSF variables) showed strong associations of UPSIT error score with age and diminished cognition, either alone or in combination (table e-2). [Table 2](#T2){ref-type="table"} shows comparable analyses in the reduced sample, now including CSF data. Models 1, 2, and 3 in [table 2](#T2){ref-type="table"} (supplemental materials) indicate no association of UPSIT error score with age, a trend with cognitive score (*p* = 0.06), but a strong association with CSF t-tau/Aβ~1-42~ (*p* = 0.003). Model 4 suggests that the trend association with cognition was unapparent after adjustment for age (*p* = 0.145). Model 5 confirms the absence (in adjusted models) of any association between OI and age, and it shows the absence of a material effect of age adjustment on the association of OI with CSF t-tau/Aβ~1-42~. Model 6 indicates that any association of OI with cognition became unapparent after the inclusion of CSF t-tau/Aβ~1-42~ (RBANS, *p* = 0.151; CSF t-tau/Aβ~1-42~, *p* = 0.004). Model 7, which includes all the described variables, made these findings clearer by suggesting that OI was predicted by its relationship with CSF t-tau/Aβ~1-42~ (*p* = 0.005) regardless of age, cognition, *APOE* ε4 status, sex, or education (figure e-3). This last model explained 19.7% of the variance in OI score (*F*~7,90~ = 3.68, *p* \< 0.00258). Both sensitivity analysis variants of model 7 produced nearly identical results (in the first analysis, *F*~12,85~ = 2.47, *p* \< 0.00993; in the second, *F*~7,83~ = 2.59, *p* \< 0.0236). The latter reduced model still explained 15.9% of the variance in OI score. Other similar multiple linear regression analyses (not shown) essentially reproduced the findings of model 7, substituting t-tau or P~181~-tau alone or the ratio of P~181~-tau/Aβ~1-42~ as independent CSF biomarker predictors.

###### 

Estimated coefficients from stepwise multiple linear regression modeling to predict UPSIT error score
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DISCUSSION {#s3}
==========

We investigated relationships of performance in OI with global cognitive scores, established AD risk factors, and several CSF biomarkers known to predict subsequent dementia. Our main finding was that a decrease in OI was associated with increasing CSF biomarker evidence of AD pathology. This association survived adjustment not only for sex, educational attainment, *APOE* ε4 carrier status, and potential brain and olfactory health history confounders but also for age or cognitive score. The relationships of OI performance with age and cognitive ability recapitulate earlier findings.^[@R11],[@R12]^ In the present sample, however, the relationship of OI with cognitive performance appears to be spurious because it represents the conjoint (confounded) relationship of both variables with the CSF biomarkers. We suggest that the relationship between OI and age (observed in the full dataset) may similarly represent a confounded association of these 2 measures with AD pathology (hence with related impairment in OI). To the best of our knowledge, there has been no previous direct demonstration that the association of OI with cognition is driven by a confounded relationship of both variables with AD pathology.

Overall, we observed no correlation of OI with CSF Aβ~1-42~ levels alone. Such a relationship was observed, however, among individuals whose CSF Aβ~1-42~ levels were in the lowest quartile. This subgroup had a greater proportion of *APOE* ε4 carriers (48%), which was close to the proportion typically seen in patients with AD. Thus, impairment in OI may in fact reflect cerebral accumulation of Aβ in these sicker participants, consistent with observations with amyloid PET.^[@R6]^ This notion was reinforced in our work by a statistically significant interaction between *APOE* ε4 carrier status and CSF Aβ~1-42~ levels as predictors of OI performance. The same was not so for global cognition, suggesting that OI may be an earlier indicator of accumulated pathology before symptom onset. Related recent work in transgenic mice expressing human *APOE* ε4 vs ε3 demonstrated genotype-specific structural differences in midlife. These modifications appear to precede later functional differences and increasing structural abnormality in brain regions related to olfaction.^[@R27]^

More generally, OI deficit is associated with presymptomatic AD pathology.^[@R5]^ Reduced structural integrity of brain regions that subserve olfaction appears especially vulnerable to such pathology. These changes include reduced entorhinal cortical thickness and hippocampus and amygdala volumes,^[@R6],[@R16],[@R28]^ as well as fibrillar amyloid accumulation in the posterior cingulate, temporoparietal, and lingual cortical regions.^[@R6],[@R29]^ Data from ^15^O-H~2~O-PET experiments on olfactory-evoked regional cerebral blood flow also demonstrate that patients with AD have a pattern of functional activation different from healthy controls. Specifically, regional cerebral blood flow in the right frontotemporal area shows a correlation with OI.^[@R30]^ CSF clearance is reduced in AD, relating to increased amyloid accumulation. Finally, dynamic monitoring of CSF has confirmed that the fluid reaches the nasal turbinates and clears through the cribriform plate.^[@R31]^

We note that our findings appear to contradict one recent report in which OI appeared not to be related to brain accumulation of amyloid as revealed by PET.^[@R32]^ As we did, the authors of that study attempted to control for known detrimental olfactory health issues. They chose to exclude participants with such issues. In addition, the earlier research was characterized by intervals ranging up to 5 years between tests of OI and PET scans, whereas our work consistently tested OI within 3 months of CSF collection. A recent study demonstrated that OI deficits are more readily detected in patients with acute brain trauma when olfactory testing is performed within days of injury.^[@R33]^ Recent PET studies of olfactory sensory neurons in lesioned, aging, or AD-like animal models further support this point.^[@R34]^

Limitations of this study include its high proportion of women and participants\' level of educational attainment, attributes that are common in aging volunteer cohorts. Although we attempted to control for these factors in multivariable models, participants who volunteered for lumbar punctures may be an even more select population, an important concern because these 100 participants produced our most informative findings. Because our results come from cross-sectional observations only, it remains unknown whether altered biomarker levels represent a process of ongoing change and, if so, the rate at which such change is accumulating. Longitudinal studies for this purpose are now in progress, as are studies assessing the physical accumulation of amyloid and tau with specific PET tracers. Lastly, we acknowledge that our failure to observe a relationship between OI and age in the restricted sample may result from the limited sample size of the CSF donor participant pool. Generally, age is reported to be the strongest known predictor of impaired OI^[@R35],[@R36]^ and the best known predictor of AD dementia. However, at least some of this age-related loss in olfactory function may relate to factors unrelated to AD pathogenesis (e.g., deterioration of nasal epithelium or calcification of the cribriform plate^[@R36]^).

While impaired OI may in fact help identify persons who could for various reasons eventually have cognitive impairment, we strongly urge that our present cross-sectional results not be regarded as rationale for clinical use of olfactory testing as an AD diagnostic. We suggest, however, that OI may serve for research purposes as a simple and inexpensive indicator of evolving AD pathology. Indeed, we are exploring its use as a biomarker in clinical trials among asymptomatic persons at risk of later dementia symptoms. In this and other ways, OI may add valuably to the measures available for AD prevention research.
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